Phase 3 N=49 Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Percentage of Patients With Control of Steatorrhea — 46.9; 42.9 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
Endocrine Tumors
Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001
Phase 3 N=119 Reducing Dynamic Hyperinflation Through Breathing Retraining
Pulmonary Disease · COPD
Primary: Exercise Duration (Time Walked on the Constant Workrate Treadmill Test) — 15.2; 17.6 minutes — p=0.63
Phase 3 N=2,640 Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
Influenza
Primary: Number of Participants With Common Hypersensitivity Reactions as Measure of Safety — 31; 21 participants
Phase 3 N=50 An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion
Neuromuscular Scoliosis
Primary: Time to Achieve Target MAP — 9.2 minutes
Phase 3 N=764 Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Schizophrenia
Primary: Time to First Relapse Event — 616; 603 days — p=0.0191
Phase 3 N=243 Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
Visual Impairment · Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Average BCVA Change From Month 1 Through Month 6 to Baseline — 14.6; 4.8 Letters
Phase 3 N=40 Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
Pain · Sickle Cell Disease
Primary: Acute Chest Syndrome — 2; 1 participants
Phase 3 N=221 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
HIV-1 Infection
Primary: Number of Participants With Clinical Efficacy — 76; 73 participants
Phase 3 N=2,628 CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
Pneumonia
Primary: Risk of Treatment Failure. — 267; 253 participants
Phase 3 N=340 Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Schizophrenia
Primary: Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score. — -8.9; -5.0; -15.2; -8.3 Units on a scale — p=0.0005
Phase 3 N=515 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Pulmonary Fibrosis
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -239.91; -114.65 mL/year — p=<0.0001
Phase 3 N=527 Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
Pneumonia
Primary: Treatment Failure at 48 Hours (Two Full Days After Enrollment) — 20; 21 participants
Phase 3 N=212 Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
Infection · Multiple Myeloma
Primary: Proportion of Patients Experiencing a Serious Bacterial Infection — 12.5; 6.8; 15.9 percentage of participants — p=0.218
Phase 3 N=133 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder · Tic Disorder
Primary: Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS). — -13.35; -16.94; -7.09 Units on a scale — p=0.0020